Press release – Page 2 – HepaRegeniX GmbH

HepaRegeniX GmbH to deliver an oral presentation of preclinical results on MKK4 inhibition in liver regeneration at The Liver Meeting® 2020

Preclinical data demonstrate efficacy of MKK4 inhibitors in liver regeneration and experimental acute and chronic liver disease models...

11/10/2020

By p3889712020, Press releaseComments Off

HepaRegeniX GmbH hires industry veteran Dr David Shapiro as Senior Medical Advisor

Preclinical data demonstrate efficacy of MKK4 inhibitors in liver regeneration and experimental acute and chronic liver disease models...

10/20/2020

By p3889712020, Press releaseComments Off

HepaRegeniX GmbH achieves successful proof of efficacy in acute liver disease models for selected MKK4 inhibitors

Preclinical data demonstrate efficacy of MKK4 inhibitors in liver regeneration and experimental acute and chronic liver disease models...

07/07/2020

By p3889712020, Press releaseComments Off

HepaRegeniX GmbH secures Series B Financing in excess of € 11 Mio. to advance first drug candidate to the clinic

Preclinical data demonstrate efficacy of MKK4 inhibitors in liver regeneration and experimental acute and chronic liver disease models...

01/21/2020

By p3889712020, Press releaseComments Off

HepaRegeniX GmbH Raises € 9 million in a Series A Financing to Develop Kinase Inhibitors for the Treatment of Acute and Chronic Liver Diseases

HepaRegeniX develops a new and unique therapeutic concept for the treatment of liver diseases, discovered by Prof. Lars Zender and his research group...

01/05/2017

By p3889712017, Press releaseComments Off